European Oncology and Haematology最新文献_第6页

The Management of Chronic Myeloid Leukaemia (CML) Patients with Refractory Disease – Focusing on the Opinions of CML-treating Physicians 慢性髓性白血病(CML)难治性疾病的治疗——关注治疗CML的医生的意见

European Oncology and Haematology Pub Date : 2017-01-01 DOI: 10.17925/EOH.2017.13.01.15

A. E. Eşkazan

引用次数: 0

What Happens when the Cost of Cancer Care Becomes Unsustainable 当癌症治疗的成本变得不可持续时会发生什么

European Oncology and Haematology Pub Date : 2017-01-01 DOI: 10.17925/EOH.2017.13.02.108

S. Simoens, W. Harten, G. Lopes, A. Vulto, K. Meier, N. Wilking

{"title":"What Happens when the Cost of Cancer Care Becomes Unsustainable","authors":"S. Simoens, W. Harten, G. Lopes, A. Vulto, K. Meier, N. Wilking","doi":"10.17925/EOH.2017.13.02.108","DOIUrl":"https://doi.org/10.17925/EOH.2017.13.02.108","url":null,"abstract":"C ancer places a heavy burden on healthcare systems. The cost of cancer drugs is increasing, driven largely by the introduction of new, ever more innovative cancer treatments. This raises questions about value for money and the future sustainability of cancer care, and presents significant challenges for decision-makers in providing all patients with access to treatments and effective new cancer medicines. The aims of this article are to provide an understanding of how sustainability in cancer care is defined, what signs indicate that the limits of sustainability are being reached, and what potential impact this may have on patients with cancer within Europe. Each country is faced with making difficult decisions about the allocation of healthcare resources to cancer care, to best meet the health needs of their patients. Determining the value of individual cancer drugs can help to inform these decisions, because premium pricing for incremental innovation is no longer sustainable. When the cost of cancer care becomes unsustainable, countries may be forced to restrict health expenditure by limiting demand, cutting spending and reducing investment. This can lead to restricted access to treatment. New, innovative cancer treatments must provide greater value than current options, and measures are needed to contain and reduce expenditure and make best use of scarce resources, without impeding access to effective and safe treatments for all patients.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"76 1","pages":"108"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86922210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

Potential Solutions for Sustaining the Costs of Cancer Drugs 维持抗癌药物成本的潜在解决方案

European Oncology and Haematology Pub Date : 2017-01-01 DOI: 10.17925/EOH.2017.13.02.102

G. Lopes, A. Vulto, N. Wilking, W. Harten, K. Meier, S. Simoens

{"title":"Potential Solutions for Sustaining the Costs of Cancer Drugs","authors":"G. Lopes, A. Vulto, N. Wilking, W. Harten, K. Meier, S. Simoens","doi":"10.17925/EOH.2017.13.02.102","DOIUrl":"https://doi.org/10.17925/EOH.2017.13.02.102","url":null,"abstract":"T he growing burden of cancer urgently requires sustainable solutions to ensure continued access to effective and safe treatments for all patients within Europe. The aim of this article, the third in a series of perspectives, is to discuss potential approaches to sustain cancer care and increase patient access to treatments. Much work remains to ensure the sustainability ceiling (where costs of care exceed the benefits) is not reached. Immediate steps must be taken to avoid this, including patient education to encourage earlier diagnosis, use of treatment-response biomarkers, improving efficiency of healthcare systems, use of managed-entry agreements, introduction of value-based medicines with measurable outcomes and use of less expensive medicines. Here we discuss these potential solutions with a focus on reducing the cost of cancer drugs, using biosimilar medicines as an example. Biosimilar and generic medicines offer a costeffective treatment option that may help combat the substantially increasing costs of cancer drugs. Competition from biosimilar medicines is expected to drive a decrease in the cost of medicines, resulting in increased affordability and access to therapy, and therefore a greater number of patients could be treated. However, various barriers must be overcome to increase the uptake of biosimilar medicines and education is needed to allay misperceptions and encourage greater use.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"1 1","pages":"102"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79933854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Bmi1 – A Path to Targeting Cancer Stem Cells Bmi1 -靶向癌症干细胞的途径

European Oncology and Haematology Pub Date : 2017-01-01 DOI: 10.17925/EOH.2017.13.02.147

D. Bakhshinyan, A. Adile, C. Venugopal, Sheila K. Singh

引用次数: 2

Combined BRAF and MEK Inhibition with Vemurafenib and Cobimetinib for Patients with Advanced Melanoma Vemurafenib和Cobimetinib联合抑制晚期黑色素瘤患者的BRAF和MEK

European Oncology and Haematology Pub Date : 2017-01-01 DOI: 10.17925/EOH.2017.13.01.1A

A. Grimaldi, E. Simeone, L. Festino, V. Vanella, P. Ascierto

{"title":"Combined BRAF and MEK Inhibition with Vemurafenib and Cobimetinib for Patients with Advanced Melanoma","authors":"A. Grimaldi, E. Simeone, L. Festino, V. Vanella, P. Ascierto","doi":"10.17925/EOH.2017.13.01.1A","DOIUrl":"https://doi.org/10.17925/EOH.2017.13.01.1A","url":null,"abstract":"A cquired resistance is the most common cause of BRAF inhibitor monotherapy treatment failure, with the majority of patients experiencing disease progression with a median progression-free survival of 6-8 months. As such, there has been considerable focus on combined therapy with dual BRAF and MEK inhibition as a means to improve outcomes compared with monotherapy. In the COMBI-d and COMBI-v trials, combined dabrafenib and trametinib was associated with significant improvements in outcomes compared with dabrafenib or vemurafenib monotherapy, in patients with BRAF-mutant metastatic melanoma. The combination of vemurafenib and cobimetinib has also been investigated. In the phase III CoBRIM study in patients with unresectable stage III-IV BRAF-mutant melanoma, treatment with vemurafenib and cobimetinib resulted in significantly longer progression-free survival and overall survival (OS) compared with vemurafenib alone. One-year OS was 74.5% in the vemurafenib and cobimetinib group and 63.8% in the vemurafenib group, while 2-year OS rates were 48.3% and 38.0%, respectively. The combination was also well tolerated, with a lower incidence of cutaneous squamous-cell carcinoma and keratoacanthoma compared with monotherapy. Dual inhibition of both MEK and BRAF appears to provide a more potent and durable anti-tumour effect than BRAF monotherapy, helping to prevent acquired resistance as well as decreasing adverse events related to BRAF inhibitor-induced activation of the MAPK-pathway. Combined BRAF and MEK inhibition is the standard of care in patients with advanced BRAF-mutant melanoma.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"25 1","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82185535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Systemic Chemotherapy for Urothelial Cancer – How to Select Systemic Therapy in Bladder Cancer 尿路上皮癌的全身化疗-如何选择膀胱癌的全身治疗

European Oncology and Haematology Pub Date : 2017-01-01 DOI: 10.17925/EOH.2017.13.02.134

A. Bamias, I. Dimitriadis

引用次数: 4

Immunotherapy and Targeted Therapies in the Treatment of Non-small Cell Lung Cancer 非小细胞肺癌的免疫治疗和靶向治疗

European Oncology and Haematology Pub Date : 2017-01-01 DOI: 10.17925/EOH.2017.13.01.35

T. Nguyen-Ngoc, M. Reck, D. Tan, S. Peters

引用次数: 5

Supporting older people with cancer - Merging geriatric and oncological knowledge 支持老年癌症患者-结合老年病学和肿瘤学知识

European Oncology and Haematology Pub Date : 2016-06-01 DOI: 10.17925/eoh.2016.12.01.23

I. Hallberg

引用次数: 1

Myelodysplastic syndromes - The epigenetic model for drug development? 骨髓增生异常综合征-药物开发的表观遗传模型?

European Oncology and Haematology Pub Date : 2016-06-01 DOI: 10.17925/eoh.2016.12.01.13

G. Montalban-Bravo, G. Garcia-Manero

引用次数: 0

Investigating rare haematological disorders - A celebration of 10 years of the Sherlock Holmes symposia 调查罕见的血液病-庆祝10年的福尔摩斯专题讨论会

European Oncology and Haematology Pub Date : 2016-06-01 DOI: 10.17925/eoh.2016.12.01.55

Cappellini, D. Cassiman, T. Marinakis, H. Rosenbaum, F. Bauduer, O. Bjerrum, Cristina Fraga, D. Hughes, U. Jäger, M. Machaczka, G. Massenkeil, A. Mehta, C. Vallejo, J. Droogenbroeck, M. Wondergem, P. Huijgens, J. Villarrubia

{"title":"Investigating rare haematological disorders - A celebration of 10 years of the Sherlock Holmes symposia","authors":"Cappellini, D. Cassiman, T. Marinakis, H. Rosenbaum, F. Bauduer, O. Bjerrum, Cristina Fraga, D. Hughes, U. Jäger, M. Machaczka, G. Massenkeil, A. Mehta, C. Vallejo, J. Droogenbroeck, M. Wondergem, P. Huijgens, J. Villarrubia","doi":"10.17925/eoh.2016.12.01.55","DOIUrl":"https://doi.org/10.17925/eoh.2016.12.01.55","url":null,"abstract":"The Sherlock Holmes symposia have been educating haematologists on the need for prompt recognition, diagnosis and treatment of rare haematological diseases for 10 years. These symposia, which are supported by an unrestricted educational grant from Sanofi Genzyme, encourage haematologists to consider rare disorders in differential diagnoses. Improvement in rare disease awareness is important because diagnostics and the availability of effective therapies have improved considerably, meaning that rare haematological diseases can be accurately diagnosed and successfully managed, particularly if they are identified early. The Sherlock Holmes symposia programme includes real-life interactive clinical cases of rare haematological disorders that require awareness from the physician, to be diagnosed at an early stage. The audience are encouraged to examine each case as if they were detectives, look for clues from the clinical history and presentation, consider the potential causes, assess which tests would be required to make a definitive diagnosis and suggest optimal treatment options. To celebrate the 10-year anniversary of the Sherlock Holmes symposia, this article describes a number of clinical cases that include anaemia, thrombocytopaenia and splenomegaly among the presenting symptoms, to illustrate the importance of rigorous differential diagnosis in the identification of rare haematological disorders.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"59 1","pages":"55-61"},"PeriodicalIF":0.0,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89424793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0